View source for 18277915. NON-IMMUNOGENIC POEGMA-APTAMER CONJUGATES simplified abstract (Duke University)

=NON-IMMUNOGENIC POEGMA-APTAMER CONJUGATES=


==Organization Name==

[[:Category:Duke University|Duke University]]


[[Category:Duke University]]

==Inventor(s)==

[[:Category:Ashutosh Chilkoti of Durham NC (US)|Ashutosh Chilkoti of Durham NC (US)]][[Category:Ashutosh Chilkoti of Durham NC (US)]]

[[:Category:Bruce Sullenger of Durham NC (US)|Bruce Sullenger of Durham NC (US)]][[Category:Bruce Sullenger of Durham NC (US)]]

[[:Category:Imran Ozer of Durham NC (US)|Imran Ozer of Durham NC (US)]][[Category:Imran Ozer of Durham NC (US)]]

[[:Category:Angus Hucknall of Durham NC (US)|Angus Hucknall of Durham NC (US)]][[Category:Angus Hucknall of Durham NC (US)]]

[[:Category:Juliana Layzer of Durham NC (US)|Juliana Layzer of Durham NC (US)]][[Category:Juliana Layzer of Durham NC (US)]]

[[:Category:George Pitoc of Durham NC (US)|George Pitoc of Durham NC (US)]][[Category:George Pitoc of Durham NC (US)]]

==NON-IMMUNOGENIC POEGMA-APTAMER CONJUGATES - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18277915 titled 'NON-IMMUNOGENIC POEGMA-APTAMER CONJUGATES

The patent application discloses POEGMA-aptamer conjugates designed to reduce or eliminate the host-immune response. These conjugates consist of an aptamer linked to a POEGMA polymer with multiple side chains, each containing 1 to 6 ethylene glycol monomers in a row. Methods for producing and utilizing these conjugates, such as controlling coagulation in a subject, are also described.

* POEGMA-aptamer conjugates with reduced host-immune response
* Aptamer linked to POEGMA polymer with ethylene glycol side chains
* Side chains contain 1 to 6 monomers of ethylene glycol
* Methods for making and using the conjugates, including controlling coagulation in a subject

Potential Applications:
- Biomedical research
- Drug delivery systems
- Therapeutics for coagulation disorders

Problems Solved:
- Reduced host-immune response to aptamer conjugates
- Improved biocompatibility of polymer-drug conjugates

Benefits:
- Enhanced safety and efficacy of drug delivery systems
- Potential for targeted therapy with reduced side effects

Commercial Applications:
Title: "Enhanced Biocompatible Drug Delivery Systems with POEGMA-Aptamer Conjugates"
This technology could be utilized in pharmaceutical companies for developing safer and more effective drug delivery systems. It may also have applications in research institutions for studying coagulation disorders and developing targeted therapies.

Prior Art:
Readers interested in prior art related to this technology could explore research articles on aptamer conjugates, polymer-drug delivery systems, and biocompatibility in drug delivery.

Frequently Updated Research:
Researchers are continually exploring new methods to enhance the biocompatibility and efficacy of drug delivery systems, including the use of novel polymers and aptamer conjugates.

Questions about POEGMA-Aptamer Conjugates:
1. How do POEGMA-aptamer conjugates compare to traditional drug delivery systems in terms of biocompatibility and immune response?
2. What are the potential challenges in scaling up the production of POEGMA-aptamer conjugates for commercial use?


==Original Abstract Submitted==

Disclosed are POEGMA-aptamer conjugates with a reduced or eliminated host-immune response. An example conjugate includes an aptamer conjugated to a POEGMA having a plurality of side chains, where each side chain includes 1 to 6 monomers of ethylene glycol repeated in tandem. Also disclosed are methods of making the conjugate and methods of using the conjugate. An example method of use includes a method of controlling coagulation in a subject.



[[Category:A61K47/60]]
[[Category:A61K31/7088]]
[[Category:A61P7/02]]
[[Category:C12N15/115]]
[[Category:CPC_A61K47/60]]